Advice
Following a full submission
idursulfase (Elaprase®) is not recommended for use within NHS Scotland for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II).
Idursulfase was approved by the EMEA under exceptional circumstances and has been designated an orphan medicinal product.
The manufacturer’s justification of the treatment’s cost in relation to its health benefits was not sufficient to gain acceptance by SMC and, in addition, they did not present a sufficiently robust economic analysis.
Download detailed advice59KB (PDF)
Medicine details
- Medicine name:
- idursulfase 2mg/ml concentrate for solution for infusion (Elaprase)
- SMC ID:
- 391/07
- Indication:
- Long-term treatment of patients with mucopolysaccharidosis II (MPS II, also known as Hunter syndrome)
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 13 August 2007